News
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
2d
Zacks Investment Research on MSNHims & Hers Stock Surges 90.4% in 3 Months: What's Fueling the Rally?Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...
Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...
1d
Zacks Investment Research on MSNHims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should KnowHims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...
Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...
Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...
Explore more
Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...
Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...
Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...
The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in. | Novo ...
Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results